A first-in-human trial of Arvinas’ investigational Parkinson’s’ disease therapy, ARV-102, has been able to demonstrate a drop ...
Clinical Trials Arena on MSN1d
AC Immune reports interim outcomes from trial of Parkinson’s therapyAC Immune has reported additional interim safety and positive immunogenicity outcomes from its placebo-controlled Phase II ...
Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...
Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...
The proteins were gathered from ... Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's ...
Buntanetap showed statistically significant improvements in every primary and secondary endpoint in the per-protocol population.
It's an honor to be a part of this process to, as a basic scientist, be able to play a small role in improving the lives of ...
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback